The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic

Engelhard, Dan; Zakay‐Rones, Zichria; Shapira, Michael Y.; Resnick, Igor B.; Averbuch, Diana; Grisariu, Sigal; Dray, Lillian; Djian, Esther; Strauss-Liviatan, Nurith; Grotto, Itamar; Wolf, Dana; Or, Reuven

doi:10.1016/j.vaccine.2010.12.113

Cited by 49 publications

(44 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found a seroconversion and seroprotection rate of 42% (15/36), which is similar to rates reported on pandemic H1N1 (2009) vaccination in alloHSCT and autoHSCT patients by Issa et al [13] and Engelhard et al [15]. Previous studies of pandemic H1N1 (2009) vaccination in healthy people showed seroconversion in >90% within 21 days of vaccination [20,21].…”

Section: Discussionsupporting

confidence: 90%

“…One dose of seasonal influenza A/H1N1 vaccine is highly immunogenic in adults, while two doses will probably be needed in children younger than 9 years [21]. Recent reports support the benefit of repeated H1N1 (2009) vaccination, indicating significantly increased HI titers in response to the first and second vaccination [15,27].…”

Section: Discussionmentioning

confidence: 99%

“…Limited data are available on the immunologic responses to primary pandemic H1N1 (2009) infection and pandemic H1N1 (2009) vaccination in patients with hematologic malignancies in general and in HSCT recipients in particular [12][13][14][15]. Here, we present the results of a retrospective analysis of pandemic H1N1 (2009) vaccination response in alloHSCT recipients and its correlation with clinical and immunological characteristics.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Vaccination against pandemic H1N1 (2009) in patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vaccination against pandemic H1N1 (2009) in patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Early depletion of CD4 + T cells in allo-HSCT mice improves reconstitution of peripheral T and B cells and serum IgM levels but has less effect on serum IgG and fecal IgA recovery (7). Vaccine-unresponsiveness and low levels of IgG and IgA often persist for years in allo-HSCT patients, even after recovery of peripheral T and B cells and IgM Abs (8)(9)(10)(11). The discordance between lymphocyte reconstitution and humoral immune competency suggests that GVHD impairs not only primary lymphoid tissues, but also secondary lymphoid tissues that are required for the induction of optimal humoral immune responses.…”

mentioning

confidence: 99%

Loss of Lymph Node Fibroblastic Reticular Cells and High Endothelial Cells Is Associated with Humoral Immunodeficiency in Mouse Graft-versus-Host Disease

Suenaga

Ueha

Abe

et al. 2015

The Journal of Immunology

View full text Add to dashboard Cite

Graft-versus-host disease (GVHD) is a major risk factor for prolonged humoral immunodeficiency and vaccine unresponsiveness after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the underlying mechanisms for this immunodeficiency are poorly understood. In this article, we describe previously overlooked impacts of GVHD on lymph node (LN) stromal cells involved in humoral immune responses. In major- and minor-mismatched mouse allo-HSCT models, recipients with CD8+ T cell–mediated GVHD suffered severe and irreversible damage to LN structure. These mice were susceptible to pathogenic infection and failed to mount humoral immune responses despite the presence of peripheral T and B cells. These humoral immune defects were associated with the early loss of fibroblastic reticular cells, most notably the CD157+ cell subset, as well as structural defects in high endothelial venules. The disruption to these LN stromal cells was dependent on alloantigens expressed by nonhematopoietic cells. Blockade of the Fas-FasL pathway prevented damage to CD157+ fibroblastic reticular cells and ameliorated LN GVHD. However, blockade of CD62L- or CCR7-dependent migration of CD8+ T cells to the LN was insufficient to prevent stromal cell injury. Overall, our results highlight GVHD-associated loss of functional stromal cells and LN GVHD as a possible explanation for the prolonged susceptibility to infectious disease that is experienced by allo-HSCT patients.

show abstract

“…In addition, HSCT patients respond poorly to influenza vaccination, with response rates around 20%, as seen previously. [21][22][23][24][25] Although seroresponse rates following pretransplant vaccination were poor, we observed that patients who achieved protective Ab titers (⩾1:40) at HSCT day were more likely to maintain specific influenza immunity up to d60, supporting the strategy of pretransplant vaccination. Serum HI Ab titers of 1:40 are supposed to protective in the immunocompetent, but higher Ab levels might be required in subjects with impaired immunity.…”

Section: Discussionmentioning

confidence: 64%

Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study

Ambati

Boas

Ljungman

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

Pretransplant influenza vaccination of the donor or allogeneic hematopoietic SCT (HSCT) candidate was evaluated in a randomized study. One hundred and twenty-two HSCT recipients and their donors were assigned to three randomization groups: no pretransplant vaccination (n = 38), donor pretransplant vaccination (n = 44) or recipient pretransplant vaccination (n = 40). Specific IgG was assessed by both hemagglutinin inhibition (HI) and, in 57 patients, by an indirect influenza-specific ELISA at specified times after HSCT. Vaccinated donors had seroprotective HI titers for Ags H1 and H3 (Po 0.001) compared with the other groups at the time of donation. The titers against H1 (P = 0.028) and H3 (P o 0.001) were highest in the pretransplant recipient vaccination group until day 180 after transplantation. A significant difference was found in the specific Ig levels against pandemic H1N1 at 6 months after SCT (P = 0.02). The mean IgG levels against pandemic H1N1 and generic H1N1 and H3N2 were highest in the pretransplant recipient vaccination group. We conclude that pretransplant recipient vaccination improved the influenza-specific seroprotection rates.

show abstract

The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic

Cited by 49 publications

References 21 publications

Vaccination against pandemic H1N1 (2009) in patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis

Vaccination against pandemic H1N1 (2009) in patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis

Loss of Lymph Node Fibroblastic Reticular Cells and High Endothelial Cells Is Associated with Humoral Immunodeficiency in Mouse Graft-versus-Host Disease

Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study

Contact Info

Product

Resources

About